New Option For Chronic Fatigue SyndromeDecember 2014
By Michael Franco
To date, as many as 4 million Americans are suffering from the debilitating effects of chronic fatigue syndrome.1
After decades of research, doctors remain puzzled as to how to treat this mysterious condition that involves unexplainable, extreme fatigue.2 Unfortunately, there are no pharmaceuticals to treat chronic fatigue syndrome other than sleeping pills and antidepressants, which do not resolve the problem.3
Frustrated by a lack of treatment options, an international team of researchers has focused their attention on a group of unique molecules called roburins, which are derived from oak wood.4
Roburin-rich oak wood extract has shown tremendous promise in managing a cluster of the symptoms that define chronic fatigue syndrome.
Evidence suggests that roburins are responsible for improving the functioning of our cellular ribosomes.5 Located in nearly every cell in the body, ribosomes are the sites of protein production and are intimately involved in the function of every tissue, organ, and system.6-8
The science of “ribosomal biogenesis” is now capturing the interest of scientists as a potential method for improving energy and biological function in the aging body. 5
Hope From The Oak
Determined scientists at several research centers have discovered unique compounds in oak wood that are proving to be an effective therapy in treating chronic fatigue.
Humans have been exposed to oak wood extracts for as long as they have been storing alcoholic beverages in aged oak barrels.5 This practice was originally adopted because of the preservative effects of fresh oak on new wines and spirits, but it has continued because of the unique flavor and character the oak provides to the aging liquor.
As the roburin molecules have been isolated and analyzed in modern laboratories, they have become available for use in animal and human studies aimed at transferring some of the oak’s resilience and stress resistance to humans.
Roburins In The Human Body
Two major human studies demonstrate the potential of roburins for mitigating chronic fatigue syndrome symptoms.
In the first study, researchers were interested in understanding how roburin molecules were distributed and absorbed, as well as their compatibility in the human body.5 Following five days of oral supplementation with roburin-rich oak wood extract—three capsules of a proprietary, patented extract called Robuvit®—the scientists found a 100% increase in plasma total phenols (a general measure of absorption of molecules in this class), as well as the presence of roburin breakdown products (metabolites) in urine of healthy volunteers.
Since roburins are found only in oak wood,4 the data demonstrated vigorous absorption and conversion of roburins into substances including urolithins and ellagic acid, which are known to have potent biological activities.9
This study also revealed that the oak wood roburins trigger a complex set of biological events in the body. Using a sophisticated technology that measures changes in gene expression, the researchers were able to show that blood serum from supplemented people in the study may beneficially alter the expression of several genes in human cells in culture.5
Among the most consistent changes in gene expression induced by the serum from oak wood extract in supplemented patients had to do with the activities of ribosomes, the ultramicroscopic cellular organelles that are responsible for the “translation” of genes in DNA into specific proteins.5 Long regarded as simply tiny protein-manufacturing plants, ribosomes are now emerging as essential in the maintenance of normal cellular functions, and as key players in the science of “systemic aging” and disorders such as chronic fatigue syndrome.
Roburins And Chronic Fatigue
The clinical impact of roburin-rich oak wood extract was made evident by a second important human study, this one conducted among patients with known chronic fatigue syndrome. In the study, adults with at least five primary chronic fatigue syndrome symptoms were treated with 200 mg/day of Robuvit® oak wood extract for a minimum of six months.3 A control group that did not use the supplement was also established among patients with the same chronic fatigue symptoms. The scientists found that oak wood extract was productive in alleviating many of the most troubling symptoms of chronic fatigue.
Among those who used the oak wood extract, there were significant reductions for a multitude of key symptoms of chronic fatigue, including:
- 18% reduction in weakness and exhaustion,
- 44% reduction in unrefreshing sleep,
- 29% reduction in short-term memory impairment,
- 63% reduction in muscle pain,
- 51% reduction in joint pain,
- 33% reduction in headaches, and
- 47% reduction in tender lymph nodes in the armpit and neck.3
Additionally, impressive reductions from baseline were also found in most secondary symptoms of chronic fatigue syndrome, including:
- 51% reduction in sensitivity to noise, foods, medications, and chemicals,
- 38% reduction in dizziness,
- 58% reduction in depression,
- 49% reduction in mood swings,
- 40% reduction in weight fluctuation,
- 24% reduction in alcohol intolerance,
- 39% reduction in allergies, and
- 29% reduction in visual disturbances.
There were no significant changes from baseline in all of these parameters for the patient group not taking the oak wood extract.3
These weren’t all of the changes, though. On a standardized mood scale, supplemented subjects had significant increases in their scores on positive items including feeling active, happy, peppy, caring, calm, and loving, along with significant reductions in negative items such as feeling gloomy, fed-up, grouchy, sad, or tired. In fact, the overall mood evaluation score in supplemented subjects rose from an average of -6.93 at baseline to +4.32 at six months. For controls, the average score at baseline was -6.5 and rose only to -3.4 at six months.3
In those with chronic fatigue syndrome, scientists have found that oxidative stress levels are usually elevated.3 At the start of this study, 65% of supplemented and 70% of control patients showed elevated oxidative stress on blood tests. Following the supplementation period, control patients showed no decrease in oxidative stress, but supplemented subjects had 8 and 10% reductions at three and six months, respectively.3
A third study demonstrated the impact of oak wood extract on the response to histamine in normal subjects.10 Histamine is a substance released in the face of allergic or inflammatory stimuli, and there is some evidence suggesting that chronic fatigue syndrome may be related to excessive release of, or sensitivity to, histamine in skin, intestines, or brain tissue.11,12
In this study, female participants were randomly assigned to control or supplement groups (300 mg Robuvit®/day) for three days, followed by an injection of pure histamine into the skin.10 A normal response to this injection produces a so-called “wheal and flare” response: a raised, itchy skin wheal associated with a red flare on the skin surface and with increased microcirculation in the immediate area. Compared with control subjects, those who had supplemented with Robuvit® had a significantly smaller wheal area (28%), smaller area of redness (13%), and lower levels of circulation increase in the immediate area (49%).10 These results suggest an additional mechanism, blockade of histamine effects, for this novel roburin-rich oak wood extract’s effects on chronic fatigue syndrome.
No side effects of the oak wood extract supplementation were reported in any of the participants in these studies.3,10
Chronic fatigue syndrome remains a puzzling and frustrating condition for patients, families, and their physicians alike. Modern science has provided tantalizing clues, but so far, there has been no real progress in understanding and treating this common condition. No medication or other form of therapy is yet available to change the underlying sources of the condition.
There is now new hope for the millions of chronic fatigue syndrome sufferers, thanks to discoveries about the unique properties of roburins, a group of ellagitannins found exclusively in oak wood. These molecules undergo chemical changes in the human intestinal tract, mediated by normal healthy bacteria, which can fight chronic fatigue syndrome on several levels.
Oak wood extract has been proven effective in a clinical trial, improving almost all primary and secondary symptoms of chronic fatigue syndrome. This and other studies demonstrate intriguing possible mechanisms of action, including changes in the function of the cellular protein factories called ribosomes. Altered ribosomal function has been seen in people infected with Epstein-Barr virus, which is strongly associated with chronic fatigue syndrome. Support for ribosomal function may prove to be an entirely new approach to managing chronic fatigue syndrome.
Robuvit® is a patented and standardized oak wood extract rich in roburins. Even for those who do not suffer from chronic fatigue syndrome, oak wood extract may be considered a novel method of maintaining one’s cellular protein synthesis machinery.
If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.
- Lin JM, Resch SC, Brimmer DJ, et al. The economic impact of chronic fatigue syndrome in Georgia: direct and indirect costs. Cost Eff Resour Alloc. 2011 Jan 21;9(1):1.
- Available at: http://www.mayoclinic.org/diseases-conditions/chronic-fatigue-syndrome/basics/treatment/con-20022009. Accessed September 5, 2014.
- Belcaro G, Cornelli U, Luzzi R, et al. Improved management of primary chronic fatigue syndrome with the supplement French oak wood extract (Robuvit®): a pilot, registry evaluation. Panminerva Med. 2014 Mar;56(1):63-72.
- Horvathova M, Orszaghova Z, Laubertova L, et al. Effect of the French oak wood extract Robuvit on markers of oxidative stress and activity of antioxidant enzymes in healthy volunteers: A pilot study. Oxid Med Cell Longev. 2014:2014:639868.
- Natella F, Leoni G, Maldini M, et al. Absorption, metabolism, and effects at transcriptome level of a standardized French oak wood extract, Robuvit, in healthy volunteers: Pilot study. J Agric Food Chem. 2014 Jan 6.
- Thomson E, Ferreira-Cerca S, Hurt E. Eukaryotic ribosome biogenesis at a glance. J Cell Sci. 2013 Nov 1;126(Pt 21):4815-21.
- Yamashita D, Sano Y, Adachi Y, et al. hDREF regulates cell proliferation and expression of ribosomal protein genes. Mol Cell Biol. 2007 Mar;27(6):2003-13.
- Frank J. The ribosome-a macromolecular machine par excellence. Chem Biol. 2000 Jun;7(6):R133-41.
- Espín JC, Larrosa M, García-Conesa MT, Tomás-Barberán F. Biological significance of urolithins, the gut microbial ellagic Acid-derived metabolites: the evidence so far. Evid Based Complement Alternat Med. 2013;2013:270418.
- Belcaro G, Pellegrini L, Dugall M, Luzzi R, Cornelli U. French oak wood extract (Robuvit®) reduces the wheal and flare response to histamine and decreases capillary filtration in normal subjects. Minerva Biotecnol. 2013;25(4):199-205.
- Dechene L. Chronic fatigue syndrome: influence of histamine, hormones and electrolytes. Med Hypotheses. 1993 Jan;40(1):55-60.
- Nijs J, Meeus M, Van Oosterwijck J, et al. In the mind or in the brain? Scientific evidence for central sensitisation in chronic fatigue syndrome. Eur J Clin Invest. 2012 Feb;42(2):203-12.
- Cho HJ, Menezes PR, Hotopf M, Bhugra D, Wessely S. Comparative epidemiology of chronic fatigue syndrome in Brazilian and British primary care: prevalence and recognition. Br J Psychiatry. 2009 Feb;194(2):117-22.
- Johnston S, Brenu EW, Staines D, Marshall-Gradisnik S. The prevalence of chronic fatigue syndrome/ myalgic encephalomyelitis: a meta-analysis. Clin Epidemiol. 2013;5:105-10.
- Vincent A, Brimmer DJ, Whipple MO, et al. Prevalence, incidence, and classification of chronic fatigue syndrome in Olmsted County, Minnesota, as estimated using the Rochester Epidemiology Project. Mayo Clin Proc. 2012 Dec;87(12):1145-52.
- Werker CL, Nijhof SL, van de Putte EM. Clinical Practice: Chronic fatigue syndrome. Eur J Pediatr. 2013 Oct;172(10):1293-8.
- Hyams JS. Functional gastrointestinal disorders. Curr Opin Pediatr. 1999 Oct;11(5):375-8.
- Lakhan SE, Kirchgessner A. Gut inflammation in chronic fatigue syndrome. Nutr Metab (Lond). 2010;7:79.
- Maes M, Twisk FN, Ringel K. Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression. Psychother Psychosom. 2012;81(5):286-95.
- Chambers D, Bagnall AM, Hempel S, Forbes C. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review. J R Soc Med. 2006 Oct;99(10):506-20.
- Devanur LD, Kerr JR. Chronic fatigue syndrome. J Clin Virol. 2006 Nov;37(3):139-50.
- Lopes LF, Ruiz Miyazawa KW, de Almeida ER, et al. Epstein-Barr virus (EBV) microRNAs: involvement in cancer pathogenesis and immunopathology. Int Rev Immunol. 2013 Jun;32(3):271-81.
- Sakamoto Y, Mariya Y, Kubo K. Quantification of Epstein-Barr virus DNA is helpful for evaluation of chronic active Epstein-Barr virus infection. Tohoku J Exp Med. 2012;227(4):307-11.
- Seto E, Moosmann A, Gromminger S, Walz N, Grundhoff A, Hammerschmidt W. Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent apoptosis of primary human B cells. PLoS Pathog. 2010;6(8):e1001063.
- Yu H, Lu J, Zuo L, et al. Epstein-Barr virus downregulates microRNA 203 through the oncoprotein latent membrane protein 1: a contribution to increased tumor incidence in epithelial cells. J Virol. 2012 Mar;86(6):3088-99.
- Bhavsar RB, Makley LN, Tsonis PA. The other lives of ribosomal proteins. Hum Genomics. 2010 Jun;4(5):327-44.
- Meeus M, Mistiaen W, Lambrecht L, Nijs J. Immunological similarities between cancer and chronic fatigue syndrome: the common link to fatigue? Anticancer Res. 2009 Nov;29(11):4717-26.
- Nijs J, De Meirleir K. Impairments of the 2-5A synthetase/RNase L pathway in chronic fatigue syndrome. In Vivo. 2005 Nov-Dec;19(6):1013-21.
- Suhadolnik RJ, Peterson DL, O’Brien K, et al. Biochemical evidence for a novel low molecular weight 2-5A-dependent RNase L in chronic fatigue syndrome. J Interferon Cytokine Res. 1997 Jul;17(7):377-85.
- Andersen JB, Mazan-Mamczarz K, Zhan M, Gorospe M, Hassel BA. Ribosomal protein mRNAs are primary targets of regulation in RNase-L-induced senescence. RNA Biol. 2009 Jul-Aug;6(3):305-15.
- Wu L, Fossum E, Joo CH, et al. Epstein-Barr virus LF2: an antagonist to type I interferon. J Virol. 2009 Jan;83(2):1140-6.
- Liu WL, Lin YH, Xiao H, et al. Epstein-Barr virus infection induces indoleamine 2,3-dioxygenase expression in human monocyte-derived macrophages through p38/mitogen-activated protein kinase and NF-κB pathways: impairment in t cell functions. J Virol. 2014 Jun 15;88(12):6660-71.
- Olausson P, Gerdle B, Ghafouri N, Larsson B, Ghafouri B. Identification of proteins from interstitium of trapezius muscle in women with chronic myalgia using microdialysis in combination with proteomics. PLoS One. 2012;7(12):e52560.
- Fok V, Mitton-Fry RM, Grech A, et al. Multiple domains of EBER 1, an Epstein-Barr virus noncoding RNA, recruit human ribosmal protein L22. RNA. 2006;12:872-82.
- Vanzi F, Vladimirov S, Knudsen CR, Goldman YE, Cooperman BS. Protein synthesis by single ribosomes. RNA. 2003 Oct;9(10):1174-9.
- Cooper GM, Hausman RE. The Cell. A Molecular Approach. 2nd Edition. Sunderland (MA): Sinauer Associates; 2000.
- Connolly K, Rife JP, Culver G. Mechanistic insight into the ribosome biogenesis functions of the ancient protein KsgA. Mol Microbiol. 2008 Dec;70(5):1062-75.
- Sun D, Luo M, Jeong M, et al. Epigenomic profiling of young and aged HSCs reveals concerted changes during aging that reinforce self-renewal. Cell Stem Cell. 2014 May 1;14(5):673-88.
- Tsai YC, Greco TM, Cristea IM. Sirtuin 7 plays a role in ribosome biogenesis and protein synthesis. Mol Cell Proteomics. 2014 Jan;13(1):73-83.